MedTrace Logo

Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection

NCT04775797 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2022-11-21

No results posted yet for this study

Summary

This three-part, Phase 1 protocol will be the first clinical study of AB-836. Parts 1 and 2a/b will be a Phase 1a SAD/MAD of AB-836 in healthy adult subjects. Part 3 will be a Phase 1b dose-ranging assessment of AB-836 in non-cirrhotic Chronic Hepatitis B (CHB) subjects.

Conditions

  • Chronic Hepatitis

Interventions

DRUG

AB-836

Capsules or Tablets

DRUG

Placebo

Capsules of Tablets

DRUG

AB-836

Tablets

DRUG

Placebo

Tablets

DRUG

Nucleos(t)ide Analogue

Tablets

Sponsors & Collaborators

  • Arbutus Biopharma Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-25
Primary Completion
2022-11-17
Completion
2022-11-17

Countries

  • Australia
  • Canada
  • Hong Kong
  • Moldova
  • New Zealand
  • South Korea
  • Thailand
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04775797 on ClinicalTrials.gov